她不是不想工作，也不是不想回家，而是不敢。 公司、公共场合，甚至自己家……患上银屑病之后，只要是有人的地方，小雅都不情愿前往。这是银屑 病患者普遍会存在的心理——"病耻感"。他们为身上斑驳的皮损而羞耻，把自己困在了方寸之间。 天津市中医药研究院附属医院皮肤科主任医师张理涛明白，银屑病完全治愈还有一条漫长的路要走，但 在治疗的同时，他还要做的，就是帮助患者战胜病耻感，勇敢踏出回归社会的第一步。 "自我隔离"的银屑病患者，迎来新的治疗希望 2025年底，张理涛接诊了一位中重度的斑块状银屑病患者小雅。 小雅的处境让他感到特别惋惜。第一次面诊，39岁的小雅被父亲领着，蓬头垢面，身体肥胖，神情沮 丧、萎缩，对自己的外在形象满不在乎。张理涛了解到，小雅虽然早已结婚，却不和丈夫同住，也没有 孩子，一直住在娘家。 更让张理涛诧异的是，小雅本科毕业后只工作了几天便辞职回家，自此就在父母家开启了她的宅居生 活，到现在已经持续了十几年。 不工作，不出门，不社交，让小雅错失十几年正常社会生活的，正是她自己沉重的心理枷锁。小雅说， 她老是觉得这个病治不好，而且皮损被看到的话，很丢人。 这种"自我隔离"在银屑病群体中并不罕见，过往反复的 ...

Core Viewpoint - The company announced that its subsidiary, Stone Pharma, has achieved positive topline results in a Phase III clinical trial for its biosimilar drug, Secukinumab injection, aimed at treating moderate to severe plaque psoriasis [1][2] Group 1: Product Development and Clinical Trials - The product, Secukinumab injection, is a fully human IgG1 monoclonal antibody that specifically binds to IL-17A, a key molecule in the pathogenesis of psoriasis [1] - The Phase III clinical trial was a multicenter, randomized, double-blind, parallel, positive-controlled equivalence study designed to verify the consistency of efficacy between the product and Cosentyx in treating moderate to severe plaque psoriasis patients [2] - The primary endpoint of the study was the proportion of patients achieving a 75% improvement in the Psoriasis Area and Severity Index (PASI-75) score from baseline at week 12, which the study successfully met [2] Group 2: Market Context and Patient Impact - There are over 7 million psoriasis patients in China, highlighting a significant market opportunity for effective treatments [1] - The safety profile of the product was found to be good, with no new or unexpected safety signals, indicating it may meet the long-term safety needs of patients [2] - The detailed data from the study will be published in upcoming academic conferences and journals, which may further validate the product's efficacy and safety [2]

Core Viewpoint - The announcement from XinNuoWei indicates that its subsidiary, Jushi Biopharma, has achieved top-line analysis data from the Phase III clinical trial of its drug, Secukinumab injection, which is a fully human IgG1 monoclonal antibody and a biosimilar to Cosentyx [1] Group 1: Product Development - Secukinumab is developed as a biosimilar to Cosentyx, which has been approved in China for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa [1] - The efficacy and safety of Cosentyx have been widely recognized in the medical community [1] Group 2: Market Context - Psoriasis is a chronic, inflammatory, systemic disease related to the immune system, with approximately 7 million patients suffering from psoriasis in China [1] - Interleukin (IL)-17A, primarily produced by activated T cells, is a key molecule in the pathogenesis of psoriasis [1] Group 3: Mechanism of Action - Secukinumab specifically binds to IL-17A, blocking the signaling of the IL-17 receptor, thereby inhibiting the inflammation associated with psoriasis [1]

Core Viewpoint - The launch of the first domestically produced IL-23p19 monoclonal antibody, Pikangqibai injection, marks a significant milestone in the treatment of psoriasis in China, providing patients with a more effective and convenient treatment option [1][2]. Group 1: Product Launch and Significance - Pikangqibai injection is the first IL-23p19 monoclonal antibody developed in China, breaking the reliance on imported drugs for this treatment [2]. - The first prescription for Pikangqibai was issued at Peking University People's Hospital, indicating its availability in the Beijing region [1]. - The introduction of this drug represents a technological breakthrough in the long-term management of psoriasis, offering a new quarterly dosing regimen [3]. Group 2: Patient Impact and Treatment Efficacy - Approximately 7 million people in China suffer from psoriasis, with a significant portion requiring systemic treatment due to the chronic nature of the disease [1]. - Clinical trial data from the CLEAR-1 study shows that 80.3% of patients achieved a PASI 90 response by week 16, making it the first IL-23p19 antibody to surpass this threshold in a registered phase III trial [2]. - The quarterly dosing schedule not only reduces the treatment burden for patients but also maintains long-lasting efficacy, which is crucial for managing chronic conditions like psoriasis [3].

Group 1 - The core point of the article is that Junshi Biosciences has received acceptance for its new drug application for JS005, a monoclonal antibody targeting IL-17A, for the treatment of moderate to severe plaque psoriasis in adults [1] - JS005 is a recombinant humanized monoclonal antibody that specifically targets IL-17A, which is associated with autoimmune diseases such as psoriasis, rheumatoid arthritis, and ankylosing spondylitis [1] - The drug works by binding with high affinity to IL-17A and selectively blocking its interaction with receptors IL-17RA/IL-17RC, thereby inhibiting downstream signaling pathways and the release of inflammatory factors [1] Group 2 - Psoriasis is a common chronic, relapsing, inflammatory, and systemic immune-mediated disease, with a prevalence rate in China reaching 0.47% in 2008, significantly higher than 0.12% in 1984 [2] - Moderate to severe psoriasis patients have an increased risk of metabolic syndrome and atherosclerotic cardiovascular diseases, as well as mental health issues such as depression, anxiety, and suicidal tendencies [2] - Psoriasis severely impacts the physical and mental health of patients, highlighting the need for effective treatment options [2]

Summary of Johnson & Johnson (NYSE: JNJ) 2025 Conference Call Company Overview - **Company**: Johnson & Johnson (J&J) - **Date of Conference**: November 17, 2025 - **Key Speakers**: Candace Long (Worldwide VP Immunology Global Commercial Strategy), David Lee (Global Immunology Therapeutic Area Head) Key Points Icotrokinra Development - **Product Description**: Icotrokinra is the first targeted oral peptide selective to the IL-23 receptor, seen as a transformative therapy for psoriasis [3][4] - **Clinical Data**: Phase three studies show it provides complete skin clearance and favorable safety, positioning it as a first-line systemic therapy for moderate to severe psoriasis [3][4] - **Market Opportunity**: Approximately 5 million Americans with moderate to severe psoriasis or inflammatory bowel disease (IBD) are not currently using biologic therapies, indicating a significant market opportunity [6] - **Approval Timeline**: Submission for regulatory approval was made in July 2025, with a confident expectation for a 2026 launch [4][5] Competitive Positioning - **Head-to-Head Studies**: Ongoing studies against Stelara, a leading biologic therapy, are expected to demonstrate superior efficacy [10][11] - **Manufacturing Capability**: J&J has invested heavily in manufacturing capabilities to meet global demand for Icotrokinra, ensuring readiness for large-scale launches [12] Market Expansion - **Impact on Biologics**: The introduction of Icotrokinra is expected to elevate discussions between clinicians and patients, potentially increasing the overall utilization of biologics [13][15] - **Patient Insights**: A study indicated that over 90% of patients currently on injectable therapies would prefer to switch to an oral option with similar efficacy and safety [18] Future Indications - **Expansion Beyond Psoriasis**: Pivotal studies for Crohn's disease and ulcerative colitis are underway, with positive initial data from the ulcerative colitis studies [5][22] - **Adolescent Studies**: Ongoing studies include adolescent populations to ensure comprehensive data at launch [22] Tremfya Performance - **Current Growth**: Tremfya is experiencing growth in psoriasis and psoriatic arthritis indications, with a focus on inhibiting structural damage in psoriatic arthritis [28][29] - **Market Share**: Over 50% of new patient starts in the IL-23 class for ulcerative colitis are attributed to Tremfya, indicating strong market penetration [30] Imavi Launch - **Unique Positioning**: Imavi is the first FcRn therapy with broad applicability across multiple patient segments, showing promise in myasthenia gravis [45][46] - **Market Potential**: Expected to be a $5 billion asset, with early signs of strong interest from neurologists for first-line use [47] Strategic Acquisitions - **Focus on Atopic Dermatitis and Respiratory Diseases**: J&J has secured multiple assets to address unmet needs in atopic dermatitis and respiratory diseases, which are large and underserved markets [51][52] - **Innovative Mechanisms**: The company is exploring various mechanisms, including IL-31 and TSLP, to enhance treatment efficacy in these complex diseases [54][56] Conclusion - **Overall Strategy**: J&J is focused on advancing its immunology portfolio through innovative therapies, strategic acquisitions, and a commitment to addressing significant unmet medical needs across various indications [58][59]

Core Viewpoint - The approval of Roflumilast cream (ZORYVE) by the National Medical Products Administration (NMPA) represents a significant advancement for patients with plaque psoriasis, offering a new treatment option in the Chinese market [1][2]. Company Summary - East China Pharmaceutical's subsidiary, Hangzhou Zhongmei East China Pharmaceutical Co., Ltd., has received the acceptance notice for the marketing application of Roflumilast cream (ZORYVE) 0.3% [1]. - Roflumilast is a highly selective non-steroidal phosphodiesterase-4 (PDE4) inhibitor, which has shown significant clinical advantages over previously approved topical psoriasis treatments [1][2]. - The cream is expected to enhance the company's core competitiveness in dermatology and innovative topical formulations, providing new momentum for long-term development [3]. Industry Summary - The psoriasis drug market in China has rapidly grown from $604 million in 2018 to $1.436 billion in 2022, with a compound annual growth rate (CAGR) of 24.2%, significantly outpacing global growth [3]. - The market size for psoriasis drugs in China is projected to reach 13.9 billion yuan in 2023 and is expected to grow to 89.4 billion yuan by 2032, with a CAGR of 59.1% [3]. - There is a substantial unmet clinical need for psoriasis treatments, indicating strong growth potential and development space in the Chinese market [2].

Core Viewpoint - Junshi Biosciences announced positive results from the Phase III clinical study of its humanized anti-IL-17A monoclonal antibody JS005 for the treatment of moderate to severe plaque psoriasis [1] Group 1: Clinical Study Results - The study was led by Professor Zhang Jianzhong from Peking University People's Hospital and conducted across 60 research centers nationwide [1] - The primary objective was to achieve at least a 90% improvement in the Psoriasis Area and Severity Index (PASI 90) and a static Physician's Global Assessment (sPGA) score of 0 or 1 at week 12, comparing JS005 to a placebo [1] - Results indicated that JS005 significantly improved psoriasis lesions and severity compared to the placebo, with a higher proportion of participants achieving an sPGA score of 0 or 1 [1] Group 2: Safety and Regulatory Plans - The safety profile of JS005 was found to be good among participants with moderate to severe plaque psoriasis [1] - The company plans to submit a marketing authorization application for the product to regulatory authorities in the near future [1]

Core Viewpoint - Huadong Medicine's subsidiary has received approval for the Phase III clinical trial of MC2-01 cream for treating plaque psoriasis, marking a significant step towards clinical application and enhancing the company's portfolio in dermatological formulations [1][2][3] Group 1: Product Development and Market Potential - MC2-01 cream is a fixed-dose combination of calcipotriene and betamethasone, designed for the topical treatment of adult plaque psoriasis, including scalp psoriasis [2][3] - The Chinese psoriasis treatment market is rapidly growing, with projections estimating it will reach USD 3.25 billion by 2025 and further increase to USD 9.94 billion by 2030 [2] - Approximately 80%-90% of psoriasis patients globally have the plaque type, indicating a significant demand for effective treatment options in China, where the number of plaque psoriasis patients is expected to reach 6.168 million by 2030 [3] Group 2: Competitive Advantage and Product Pipeline - Huadong Medicine has established a comprehensive pipeline in the autoimmune field, with over 20 innovative products in development, covering various conditions including psoriasis, atopic dermatitis, and more [4] - The company has created a "golden product combination" in psoriasis treatment, including monoclonal antibodies, oral medications, and topical formulations, aiming to provide a wide range of options for patients [5][6] - The company is actively pursuing collaborations and has received approvals for multiple products, enhancing its competitive position in the dermatological market [6] Group 3: Strategic Vision and Future Outlook - Huadong Medicine aims to become a globally influential innovative pharmaceutical company, focusing on accelerating strategic layouts across multiple fields and delivering breakthrough treatment solutions for patients [7]

Core Viewpoint - The article highlights the challenges and advancements in the treatment of psoriasis, emphasizing the importance of comprehensive management and patient education in improving quality of life for patients suffering from this chronic condition [1][2][3][4][5]. Group 1: Disease Overview - Psoriasis is described as a chronic, recurrent, inflammatory, and systemic disease influenced by genetic and environmental factors, with no current cure available [2][3]. - The disease predominantly affects young adults, with approximately two-thirds of patients experiencing symptoms before the age of 40, leading to significant psychological distress [2][3]. Group 2: Treatment Advancements - Traditional therapies for psoriasis have shown limited effectiveness and significant side effects, making complete clearance of skin lesions nearly impossible [3]. - The introduction of biologic agents since 2019 has dramatically improved treatment outcomes, with clearance rates reaching up to 90% [3]. Group 3: Patient Experiences - A case study of a patient named Wang Jie illustrates the transformative impact of biologic treatment, leading to significant improvement in his condition and a renewed sense of confidence [3]. - The article also highlights the dangers of relying on unproven folk remedies, which can lead to severe health complications, as seen in a case involving a child patient [3]. Group 4: Comprehensive Management Approach - Long-term management is crucial for controlling psoriasis, which includes not only medication but also screening for comorbidities and lifestyle interventions [4]. - The article stresses the need for personalized treatment strategies and the importance of patient education to foster informed decision-making [4]. Group 5: Social Support and Awareness - The article mentions the "This Place Has No Silver" initiative by Johnson & Johnson, which aims to promote educational and professional equity for patients with psoriasis, leveraging AI to enhance understanding and support [5]. - The intersection of medical innovation and societal awareness is seen as vital for empowering patients and restoring their confidence in social interactions [5].